Betty K. Hamilton, MD, discusses findings from a study comparing gilteritinib vs placebo post-allogeneic hematopoietic cell transplantation for the treatment of patients with FLT3-ITD-positive acute myeloid leukemia.
Betty K. Hamilton, MD, associate professor of medicine at the Cleveland Clinic, discusses findings from a study comparing gilteritinib (Xospata) vs placebo post-allogeneic hematopoietic cell transplantation (HCT) for the treatment of patient with FLT3-ITD-positive acute myeloid leukemia (AML)
An exploratory analysis on health-related quality of life (HRQOL) using FACT-bone marrow transplant (BMT), FACT-Leukemia, and EQ-5D-5L measures found there to be no significant differences between patients treated with gilteritinib and placebo. Both arms showed improvements post-HCT. While there were more TEAEs with gilteritinib, patient-reported tolerability remained similar between groups.
Transcription:
0:09 | We found no significant differences in quality-of-life between patients receiving gilteritinib vs placebo. There we used several health-related quality-of-life measures, including the FACT-BMT, the FACT-Leukemia, and the EQ-5D-5L, which was an international health-related quality-of-life measure. Across all domains, there were no significant differences in quality-of-life between patients who received gilteritinib vs placebo. We did find that health-related quality-of-life did improve over time post transplant, [which was] consistent with other studies. Specifically, there was a question that was investigated that evaluated treatment tolerability, whether a patient was bothered by [adverse] effects, and there was no difference in responses to that either between gilteritinib and placebo.
1:08 | In the transplant population, this is a cohort that is often cared for and followed by a transplant center, however, again, it is important to note that getting the patient's perspective and patient-reported outcomes and quality-of-life is really important. [For] these maintenance therapies, there [are] increasing data to support their use, and can not only improve survival, but also shows that it is well-tolerated.
BLA for Remestemcel-L to Treat Pediatric SR-aGVHD Resubmitted to FDA
July 10th 2024The application of remestemcel-L, a potential first-of-its-kind treatment for pediatric patients following stem cell transplants, has been resubmitted for FDA approval after addressing previous concerns.
Read More
Novel Therapy Boosts Survival After Stem Cell Transplants
July 3rd 2024Alexandra Gomez Arteaga, MD, discussed findings from a retrospective study comparing Orca-T with posttransplant cyclophosphamide graft-vs-host disease prophylaxis to assess outcomes in patients undergoing hematopoietic cell transplant.
Read More
Ponatinib, Chemo, and Transplant Shows Promise for Long-Term Survival in Ph+ ALL
June 20th 2024The phase 2 PONALFIL trial evaluating a ponatinib regimen shows promise for long-term survival in adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.
Read More